[Federal Register Volume 63, Number 172 (Friday, September 4, 1998)]
[Notices]
[Page 47312]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-23947]
[[Page 47312]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Animal Model for Age-Related Macular Degeneration and Methods for
Use Thereof
KG Csaky (NEI)
Serial No. 60/060,045 filed 25 Sept 97
Licensing Contact: Jaconda Wagner, 301/496-7735 ext. 284
The invention provides an animal model for the study of age-related
macular degeneration (ARMD). The model is an animal, any mammal, having
subretinal cells, e.g., retinal pigment epithelial (RPE) cells,
genetically modified to express vascular endothelial growth factor
(VEGF) so as to result in subretinal fibrovascular proliferation. The
invention also provides two methods: (1) for determining whether a
molecule of interest can inhabit ARMD; and (2) for determining whether
radiation can inhibit ARMD. This research has been published in Curr
Eye Res 1998 Mar; 17(3): 316-21.
Protection of Tissue From Ischemic Damage
E Murphy (NIEHS), W Chen (Duke), C Steenbergen (Duck)
DHHS Reference No. E-174-97/0 filed 25 Jul 97
Licensing Contact: Dennis Penn, 301/496-7056 ext. 211
Ischemia and reperfusion injury are significant causes of tissue
damage in diseases and conditions such as heart attack, stroke and in
organ transplantation. Scientists at the National Institute of
Environmental Health Sciences and Duke University, while investigating
the phenomena of preconditioning, have discovered and developed a
highly effective method for protecting tissues from cell injury by
ischemia by use of 12(S)-HpETE.
Previously developed treatments to prevent ischemic damage are
greatly limited in their effectiveness. TPA, routinely used to dissolve
blood clots, thereby allowing greater blood flow, does not prevent
ischemic tissue injury. Aspirin has been shown to have only a small
protective effect in the cardiovascular system. However, the above new
method demonstrates a dramatic protective effect--up to 82% recovery in
initial studies--with administered during injury, as seen in animal
models. The protective effect of 12(S)-HpETE was discovered during
investigation of the 12-lipoxygenase-related protective effect of
ischemic preconditioning and, unlike other agents, 12(S)-HpETE has no
known undesirable side effects.
Uses of such an invention may include treatment of tissue during
angioplasty and treatment of organs intended for transplantation to
limit the chance of damage.
This research was published in Circulation Research 76: 457-467,
1995.
Dated: August 28, 1998.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer.
[FR Doc. 98-23947 Filed 9-3-98; 8:45 am]
BILLING CODE 4140-01-M
